SCHEMBL19146293

SCHEMBL19146293

COc1cc2[nH]c(C)c(I)c(=O)c2cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 4/20 0.53
HPGD P15428 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PDE3B Q13370 9/20 0.49
PDE3A Q14432 9/20 0.49
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48
MPO P05164 2/20 0.47
XDH P47989 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1394736 0.87 MTNR1A (0.44) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL19146292 0.84 PDE3B (0.54) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL30462976 0.79 PDE3B (0.56) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL29030287 0.79 PDE3B (0.56) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL26035451 0.78 GRIN2D (0.45) KDM4EALDH1A1HPGDSMN1; SMN2GRIN2D
SCHEMBL8944835 0.76 PDE3B (0.52) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL19146396 0.73 NQO2 (0.60) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL7983948 0.72 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL31195781 0.72 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL5534060 0.72 GRIN2D (0.50) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731960-B2 Biheterocyclic compound Sumitomo Pharma Co., Ltd. (JP) 2023-08-22 US disclosed
US-20220380353-A1 BIHETEROCYCLIC COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2022-12-01 US disclosed
US-20210198242-A1 BIHETEROCYCLIC COMPOUND SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-07-01 US disclosed
US-10870642-B2 Biheterocyclic compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-12-22 US disclosed
US-20190308958-A1 BIHETEROCYCLIC COMPOUND SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-10-10 US disclosed
US-10323024-B2 Biheterocyclic compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-06-18 US disclosed
US-20190016711-A1 BIHETEROCYCLIC COMPOUND SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-01-17 US disclosed
WO-2017122722-A1 BIHETEROCYCLIC COMPOUND 大日本住友製薬株式会社 2017-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380353-A1 BIHETEROCYCLIC COMPOUND NPY4R, NR4A3, OGFR KDM4E 883/4885ALDH1A1 3596/4885HPGD 3175/4885
US-11731960-B2 Biheterocyclic compound NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885
US-20210198242-A1 BIHETEROCYCLIC COMPOUND NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885
US-20190308958-A1 BIHETEROCYCLIC COMPOUND NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885
US-10323024-B2 Biheterocyclic compound NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885
US-10870642-B2 Biheterocyclic compound NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885
US-20190016711-A1 BIHETEROCYCLIC COMPOUND NR4A3, NGF, OGFR KDM4E 1008/4885ALDH1A1 3217/4885HPGD 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.